Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
tirzepatide is a dual agonist (GIP/GLP-1) Peak weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) and 24.2% at 48 weeks (Phase 2) vs tirzepatide 20.9% (Phase 3) Liver fat : Retatrutide's glucagon agonism provides pronounced hepatic fat reduction (up to 82%) Regulatory status : Tirzepatide is FDA-approved
Mahdi AA, Shukla KK, Ahmad MK, et al
B cell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases
J., Roopenian, D
At Peptides Costa Rica, it is produced under strict quality standards to ensure purity, consistency, and reliability for advanced peptide applications
US$ 25.09
US$ 27.98
US$ 23.62
US$ 27.82
